quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:00:00·78d
PRRelease
Kodiak Sciences Inc logo

Final APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026

KOD· Kodiak Sciences Inc
Health Care
Original source

Companies

  • KOD
    Kodiak Sciences Inc
    Health Care

Recent analyst ratings

  • Nov 11UpdateH.C. Wainwright$24.00
  • Oct 24UpdateAnalyst$24.00
  • Sep 25UpdateBarclays$17.00
  • Sep 22UpdateJefferies$15.00
  • Aug 14UpdateAnalyst$15.00
  • Dec 9UpdateJefferies$20.00

Related

  • SEC1d
    SEC Form DEFA14A filed by Kodiak Sciences Inc
  • SEC1d
    SEC Form DEF 14A filed by Kodiak Sciences Inc
  • INSIDER7d
    SEC Form 4 filed by Borgeson John A.
  • INSIDER21d
    SEC Form 4 filed by Borgeson John A.
  • SEC23d
    SEC Form S-8 filed by Kodiak Sciences Inc
  • SEC23d
    SEC Form 10-K filed by Kodiak Sciences Inc
  • SEC23d
    Kodiak Sciences Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • PR23d
    Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022